Press Release

Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.

Global PD-1 and PD-L1 Inhibitors Market to Grow at a CAGR of 17.50% During 2022-2027, Aided by the Rising Incidences of Cancer Worldwide

According to a new report by EMR titled, ‘Global PD-1 and PD-L1 Inhibitors Market Report and Forecast 2022-2027’, the market attained a value of almost USD 30.3 billion in 2021. The industry is further expected to grow at a CAGR of 17.50% in the forecast period of 2022-2027 to reach a value of nearly USD 80.9 billion by 2027.

The global PD-1 and PD-L1 inhibitors industry is being driven by the growing prevalence of cancer around the globe, which is compelling the key market players to develop effective methods to enhance the treatment process and its efficacy. In this regard, the market players are increasingly investing in the research and development activities while employing emerging technological solutions. In addition, the growing government investments in the development of advanced healthcare facilities and the rapidly increasing geriatric population with heightened susceptibility to chronic illnesses are predicted to aid the market in the forecast period.

The increasing demand for effective cancer treatments is further leading to the development of efficient PD-1 and PD-L1 inhibitors to be used against various types of cancers. This is estimated to significantly catalyse the industry growth in the forecast period. For instance, in February 2021, Sanofi S.A. (OTCMKTS: SNYNF) announced that its PD-1 inhibitor Libtayo® (cemiplimab-rwlc) has received FDA approval to be used as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) with tumors of high PD-L1 expression.  Furthermore, another key player, namely Bristol-Myers Squibb Company (NYSE: BMY) in October 2021 announced that its programmed death-1 (PD-1) immune checkpoint inhibitor, Opdivo (nivolumab) has received approval from the European Commission to be used along with fluoropyrimidine- and platinum-based combination chemotherapy for the treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma (EAC) with tumors expressing PD-L1. Such developments are expected to positively impact the PD-1 and PD-L1 inhibitors industry in the forecast period.

Market Breakup by Type, Application, End User, and Region:

  • The market is divided, based on type, into PD-1 inhibitors and PD-L1 inhibitors.
  • On the basis of application, the market can be distributed into Hodgkin Lymphoma, Kidney Cancer, Melanoma, Non-Small Cell Lung Cancer, and others.
  • Based on end user, the industry is segregated into hospital pharmacies, retail pharmacies, and online pharmacies.
  • Region-wise, the global market for PD-1 and PD-L1 inhibitors can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Key Findings of the Report:

  • The global market for PD-1 and PD-L1 inhibitors is being driven by the rising incidences of cancer worldwide.
  • The increased demand for effective cancer treatment has significantly contributed to the market expansion.
  • Heightened investments in the healthcare sector are also aiding the industry growth.
  • The rising geriatric population, coupled with the favorable government initiatives, is further propelling the market growth.

Key Offerings of the Report:

  • The EMR report gives an overview of the global market for PD-1 and PD-L1 inhibitors for the periods (2017-2021) and (2022-2027).
  • The report also offers historical (2017-2021) and forecast (2022-2027) market information for the types, applications, end users, and major regions of PD-1 and PD-L1 inhibitors.
  • The report analyses the market dynamics, covering the key demand and price indicators in the market, along with providing an assessment of the SWOT and Porter’s Five Forces models.

The major players in the global PD-1 and PD-L1 inhibitors market are F. Hoffmann-La Roche AG, Sanofi S.A., Amgen Inc., AstraZeneca PLC, Pfizer Inc., Bristol-Myers Squibb Company, and others. The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.

About Us

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium-sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us:

Expert Market Research
Website: www.expertmarketresearch.com
Email: sales@expertmarketresearch.com
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-579

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

Similar Reports





NEWSLETTER